Endometrial Cancer
D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
- Details
ClinicalTrials.gov ID:
NCT04269200
Diagnosis Type:
NA
USOR Number:
- Address
5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767